Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00004688

Recruitment Status : Completed

First Posted : February 25, 2000

Last Update Posted : March 25, 2015

Sponsor:

Information provided by:

FDA Office of Orphan Products Development

Study Description

Brief Summary:

OBJECTIVES:

I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.

Condition or disease	Intervention/treatment	Phase
Anaplastic Astrocytoma Anaplastic Oligodendroglioma Mixed Gliomas Glioblastoma Multiforme Recurrent Brain Tumor	Drug: carmustine Drug: mercaptopurine Drug: streptozocin	Phase 2

Detailed Description:

PROTOCOL OUTLINE:

Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days 3-5, and streptozocin IV over 20 minutes on days 2-5. Patients receive treatment every 42 days, for up to 4 courses.

Completion date provided represents the completion date of the grant per OOPD records

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	35 participants
Primary Purpose:	Treatment
Study Start Date :	August 1996
Study Completion Date :	July 1998

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Brain Tumors

Drug Information available for: Mercaptopurine Carmustine Streptozocin

Genetic and Rare Diseases Information Center resources: Glioblastoma Glioma Anaplastic Astrocytoma Brain Tumor, Adult Oligodendroglioma Anaplastic Oligodendroglioma Neuroepithelioma

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Histologically proven refractory or recurrent brain neoplasms Glioblastoma multiforme Anaplastic astrocytoma Gliosarcoma Anaplastic oligodendroglioma Mixed anaplastic glioma Unequivocally progressive primary brainstem tumors following primary therapy Measurable disease --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy At least 6 weeks since prior nitrosoureas or mitomycin Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy allowed Surgery: Prior surgery allowed --Patient Characteristics-- Age: Not specified Performance status: ECOG 0-2 Karnofsky 60-100% Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT no greater than 4 times normal Renal: Creatinine no greater than 2.0 mg/dL Pulmonary: FEV1 greater than 1 L if symptomatic pulmonary disease present Other: No other concurrent malignancies Not pregnant or lactating Negative pregnancy test Fertile patients must use effective contraception

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004688

Sponsors and Collaborators

Emory University

Investigators


Study Chair:	Mark R. Gilbert	Emory University

More Information


ClinicalTrials.gov Identifier:	NCT00004688 History of Changes
Other Study ID Numbers:	199/13310 EUSM-FDR001274
First Posted:	February 25, 2000 Key Record Dates
Last Update Posted:	March 25, 2015
Last Verified:	March 1999

Keywords provided by FDA Office of Orphan Products Development:


adult anaplastic astrocytoma adult anaplastic oligodendroglioma adult brain stem glioma adult brain tumor adult glioblastoma multiforme adult infiltrating astrocytoma brain tumor	genetic condition miscellaneous sites/terms mixed gliomas nervous tissue tumors oncologic disorders rare disease recurrent adult brain tumor

Additional relevant MeSH terms:


Glioblastoma Glioma Brain Neoplasms Astrocytoma Oligodendroglioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site	Brain Diseases Central Nervous System Diseases Nervous System Diseases 6-Mercaptopurine Carmustine Streptozocin Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors

To Top